Special Issue "Antimicrobial Peptides: Development, Conjugation, and Beyond"

A special issue of Biomolecules (ISSN 2218-273X).

Deadline for manuscript submissions: closed (28 February 2018)

Special Issue Editor

Guest Editor
Prof. Dr. Suzana K. Straus

Department of Chemistry, University of British Columbia, Vancouver, BC V6T 1Z1, Canada
Website | E-Mail
Interests: antimicrobial peptides; bioconjugation; mechanism of action; structural biology; biophysical chemistry; nuclear magnetic resonance; lipid-protein interactions; protein–protein interactions; membrane-associated peptides and proteins

Special Issue Information

Dear Colleagues,

Bacterial resistance means that many researchers are looking for alternatives to currently-used antibiotics. One strategy being explored is to use antimicrobial peptides (AMPs). AMPs are considered to be viable alternatives to currently-used antibiotics, because they have a broad antimicrobial spectrum and since bacteria develop little or no resistance towards them. In addition, AMPs are ubiquitous in nature and are involved in the first line of defense in plants and animals.

Although AMPs are promising, only a few are used for systemic therapy. The number of AMPs currently being used is limited because these compounds often display adverse effects such as unknown toxicity against host cells, short circulation half-life due to protease digestion and rapid kidney clearance. To circumvent these issues, a number of strategies are being explored to improve the properties of AMPs via formulations and conjugation to biocompatible polymers. Solutions to the limitation of enzymatic degradation have been investigated by the incorporation of d-amino acids, chemical modification of the peptide (side chain groups, N and C-termini,) cyclization, as well as polymer conjugation. This Special Issue will explore recent advancements in AMP research, as well as the methods to minimize their limitations.

Prof. Dr. Suzana K. Straus
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 650 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • antimicrobial peptides (AMPs)
  • biophysical characterization
  • mode of action
  • bioconjugation of AMPs
  • limitation of enzymatic degradation
  • d-amino acids use in AMPs
  • cyclization of AMPs
  • chemical modification of AMPs

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessReview Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo
Biomolecules 2018, 8(1), 4; doi:10.3390/biom8010004
Received: 20 December 2017 / Revised: 12 January 2018 / Accepted: 12 January 2018 / Published: 19 January 2018
PDF Full-text (2144 KB) | HTML Full-text | XML Full-text
Antibiotic resistance is projected as one of the greatest threats to human health in the future and hence alternatives are being explored to combat resistance. Antimicrobial peptides (AMPs) have shown great promise, because use of AMPs leads bacteria to develop no or low
[...] Read more.
Antibiotic resistance is projected as one of the greatest threats to human health in the future and hence alternatives are being explored to combat resistance. Antimicrobial peptides (AMPs) have shown great promise, because use of AMPs leads bacteria to develop no or low resistance. In this review, we discuss the diversity, history and the various mechanisms of action of AMPs. Although many AMPs have reached clinical trials, to date not many have been approved by the US Food and Drug Administration (FDA) due to issues with toxicity, protease cleavage and short half-life. Some of the recent strategies developed to improve the activity and biocompatibility of AMPs, such as chemical modifications and the use of delivery systems, are also reviewed in this article. Full article
(This article belongs to the Special Issue Antimicrobial Peptides: Development, Conjugation, and Beyond)

Figure 1

Back to Top